Profound Medical Corp. introduced its TULSA‑AI Volume Reduction module, an AI‑driven, MRI‑guided system that expands the existing TULSA‑PRO platform to treat benign prostatic hyperplasia (BPH). The new module allows physicians to stack multiple prostate cases in a single day using the same TULSA‑PRO hardware, clinical support staff, and reimbursement codes, thereby increasing system utilization and broadening the company’s addressable market to an estimated 600,000 BPH patients annually.
The launch positions Profound as a comprehensive, incision‑free solution for the full spectrum of prostate disease. By adding a BPH‑specific module, the company can capture a larger share of the prostate treatment market, which is expected to grow as MRI‑guided ablation gains acceptance. The expanded portfolio also strengthens the competitive moat against robotic radical prostatectomy, high‑intensity focused ultrasound (HIFU), and other minimally invasive therapies.
Profound will present new clinical data at the Radiological Society of North America (RSNA) meeting in Chicago (November 30‑December 4) and the Society for Urologic Oncology (SUO) meeting in Phoenix (December 2‑5). The presentations will cover both prostate cancer and BPH outcomes, highlighting the procedure’s superior patient results and reduced risk of sexual dysfunction and incontinence compared with traditional treatments.
In Q3 2025, Profound reported revenue of $5.3 million, up 87% from $2.83 million in Q3 2024, and a gross margin of 74.3% versus 63.1% the prior year. CEO Arun Menawat said the company is “on a path to profitable growth” and that the new module will accelerate adoption across hospitals, ambulatory surgical centers, and office settings.
The combination of a larger patient base, higher utilization, and improved margins positions Profound to capture additional market share and reinforce its leadership in MRI‑guided prostate therapy. The upcoming conference presentations are expected to reinforce the clinical evidence base and support broader reimbursement and adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.